# US 2021/0261969 A1 · PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUSCULAR DISEASE OR CACHEXIA COMPRISING, AS ACTIVE INGREDIENT, miRNA LOCATED IN DLK1-DIO3 CLUSTER OR VARIANT THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0261969 A1
- Document ID: US20210261969A1
- Status: Published application
- Kind: A1
- Application number: 16/961,130
- Filed: 2019-01-09
- Published: 2021-08-26
- Earliest claimed: 2018-01-09
- Assignees: Korea Research Insttitute of Bioscienand Biotechnology
- Applicants: Korea Research Insttitute of Bioscienand Biotechnology
- Inventors: Ki-Sun KWON; Kwang-Pyo LEE; Yeo Jin SHIN; Bora LEE; Seung Min LEE
- Web page: https://patentgrep.com/patent/US20210261969A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/30: Special therapeutic applications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition for preventing or treating a muscular disease or cachexia, comprising, as an active ingredient, a miRNA located in Dlk1-Dio3 cluster or a variant thereof. In the present invention, it has been found that expression of miRNAs located in the Dlk1-Dio3 cluster is decreased as age increases. In particular, in a case where most of the miRNAs are over-expressed in fully differentiated myotubes, it has been confirmed that the diameter of the myotubes increases. In addition, also in a tumor-induced cachexia mouse model, it has been confirmed that cachexia was improved by inhibiting Atrogin-1 protein. Accordingly, the miRNA located in the Dlk1-Dio3 cluster or a variant thereof can be usefully utilized for the treatment and prevention of an Atrogin-1-dependent muscular disease and cachexia.

## Claims

### Claim 1

A method of treating a muscular disease, comprising:
administering to a subject a pharmaceutical composition comprising a miRNA located in Dlk1-Dio3 cluster or a variant thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the miRNA comprises at least one selected from the group consisting of miRNA-668, miRNA-376c, miRNA-494, miRNA-541, miRNA-377, miRNA-1197, miRNA-495, miRNA-300, miRNA-409, miRNA-544a, miRNA-379, miRNA-431, miRNA-543, and miRNA-337.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the miRNA decreases an expression level of Atrogin-1/MAFbx protein.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the miRNA directly interacts with 3′-untranslated region (3′-UTR) of a polynucleotide encoding Atrogin-1/MAFbx protein, and suppresses expression of Atrogin-1/MAFbx.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the muscular disease comprises at least one selected from the group consisting of sarcopenia, muscular atrophy, muscle dystrophy, and acardiotrophia.

### Claim 6

A method of treating a muscular disease, comprising:
administering to a subject a pharmaceutical composition comprising a vector loaded with a nucleotide encoding a miRNA located in Dlk1-Dio3 cluster or a variant thereof.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the miRNA comprises at least one selected from the group consisting of miRNA-668, miRNA-376c, miRNA-494, miRNA-541, miRNA-377, miRNA-1197, miRNA-495, miRNA-300, miRNA-409, miRNA-544a, miRNA-379, miRNA-431, miRNA-543, and miRNA-337.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the vector comprises at least one selected from the group consisting of a plasmid vector, a cosmid vector, a virus, and analogs thereof.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the virus is adenovirus or adeno-associated virus.

### Claim 10

A method of treating cachexia, comprising:
administering to a subject a pharmaceutical composition comprising a miRNA located in Dlk1-Dio3 cluster or a variant thereof.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the miRNA comprises at least one selected from the group consisting of miRNA-668, miRNA-376c, miRNA-494, miRNA-541, miRNA-377, miRNA-1197, miRNA-495, miRNA-300, miRNA-409, miRNA-544a, miRNA-379, miRNA-431, miRNA-543, and miRNA-337.

### Claim 12

The pharmaceutical composition for preventing or A method of treating cachexia, comprising as an active ingredient:
administering to a subject a pharmaceutical composition comprising a vector loaded with a nucleotide encoding a miRNA located in Dlk1-Dio3 cluster or a variant thereof.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the miRNA comprises at least one selected from the group consisting of miRNA-668, miRNA-376c, miRNA-494, miRNA-541, miRNA-377, miRNA-1197, miRNA-495, miRNA-300, miRNA-409, miRNA-544a, miRNA-379, miRNA-431, miRNA-543, and miRNA-337.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the vector comprises at least one selected from the group consisting of a plasmid vector, a cosmid vector, a virus, and analogs thereof.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the virus is adenovirus or adeno-associated virus.

### Claim at position 16

16-21. (canceled)
